| Jun 26 2024 |
July 1 Deadline Looms for Cannabis Operators to Maintain and Renew Their Licenses by Entering into Labor Peace Agreements |
Sheppard, Mullin, Richter & Hampton LLP |
| Jun 26 2024 |
The 340B ‘Saga’ Continued: HRSA, States, and Drug Manufacturers Contest 340B Contract Pharmacy Restrictions in Court |
ArentFox Schiff LLP |
| Jun 26 2024 |
FDA Issues Warning Letter Related to Allergen Labeling Practices |
Keller and Heckman LLP |
| Jun 26 2024 |
CMS Issues FAQs to Aid Pharmacies in Preparing for Medicare Part B Coverage of PrEP Medications |
McDermott Will & Schulte LLP |
| Jun 26 2024 |
United States | AIC Special Report Notes 65% Growth in H-2 a Workers in US Agricultural Sector |
Berry Appleman & Leiden |
| Jun 25 2024 |
APHIS RFI Will Seek Comments on Options for Reducing Regulations for Modified Microbes |
Bergeson & Campbell, P.C. |
| Jun 25 2024 |
This Week in 340B: June 18 – 24, 2024 |
McDermott Will & Schulte LLP |
| Jun 25 2024 |
FDA Continues Response to Contaminated Applesauce Pouches |
Keller and Heckman LLP |
| Jun 25 2024 |
‘Big in a Small Town’: How Fast Food and QSRs are Transforming Small Town Dining |
ArentFox Schiff LLP |
| Jun 25 2024 |
Trending in Telehealth: June 4 – 10, 2024 |
McDermott Will & Schulte LLP |
| Jun 25 2024 |
China’s Supreme People’s Court Releases Two Recent Patent-Related Typical Anti-Monopoly Cases |
Schwegman, Lundberg & Woessner, P.A. |
| Jun 24 2024 |
China’s Supreme People’s Court: Drug Patent Reverse Payment Agreements May Violate the Anti-Monopoly Law |
Schwegman, Lundberg & Woessner, P.A. |
| Jun 24 2024 |
USPTO Publishes Drug Patent and Exclusivity Study Report |
Foley & Lardner LLP |
| Jun 24 2024 |
Healthcare Preview for the Week of: June 24, 2024 [Podcast] |
McDermott Will & Schulte LLP |
| Jun 21 2024 |
MoCRA Compliance: Key Legal Issues for Fashion Houses with Cosmetics |
ArentFox Schiff LLP |
| Jun 21 2024 |
CCC in Turmoil? Massachusetts Legislature Urged to Place Cannabis Control Commission in Receivership |
Blank Rome LLP |
| Jun 21 2024 |
Teva and DOJ May Reach Settlement in Closely Watched AKS Lawsuit |
ArentFox Schiff LLP |
| Jun 21 2024 |
California’s Occupational Safety and Health Standards Board Votes on Naloxone Requirement |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Jun 21 2024 |
USDA Proposes Revising Section 8e Import Inspection Fee Structure |
Keller and Heckman LLP |
| Jun 20 2024 |
FDA Updates Guidance on Intentional Genomic Alterations in Animals |
Womble Bond Dickinson (US) LLP |
| Jun 20 2024 |
CCC’s Model HCA & Approval Process |
Blank Rome LLP |
| Jun 20 2024 |
Rescheduling Timeline and Exclusions |
Blank Rome LLP |
| Jun 20 2024 |
The Future of Hemp-Derived THC |
Blank Rome LLP |
| Jun 20 2024 |
MDMA DOA at FDA Advisory Committee |
Bradley Arant Boult Cummings LLP |
| Jun 20 2024 |
This Week in 340B: June 11 – 17, 2024 |
McDermott Will & Schulte LLP |
| Jun 20 2024 |
FDA Issues Final Rule Overhauling Regulation of Medical Gases |
Keller and Heckman LLP |
| Jun 20 2024 |
What’s in a Word? The Legal Battle over “Natural” in False Advertising |
Proskauer Rose LLP |
| Jun 20 2024 |
Key Farm Bill Reauthorization Priorities Officially Laid on the Table |
Van Ness Feldman LLP |
| Jun 18 2024 |
Innovate Law Episode 1 | Annette Kleiser, CEO Dalan Animal Health [Video] |
Foley & Lardner LLP |
| Jun 18 2024 |
We Get Work: Technologies and the Life Sciences Industry [Podcast] |
Jackson Lewis P.C. |
| Jun 18 2024 |
FDA Proposes Traceability Exemption for Cottage Cheese |
Keller and Heckman LLP |
| Jun 18 2024 |
May 2024 Bounty Hunter Plaintiff Claims |
Keller and Heckman LLP |
| Jun 17 2024 |
ECHA Updates Report on Key Areas of Regulatory Challenge, Addresses Micro- and Nano-Sized Materials |
Bergeson & Campbell, P.C. |
| Jun 17 2024 |
USCIS Rescheduling an Existing Biometrics Appointment |
Mintz |
| Jun 14 2024 |
NNI EHS Research Strategy: 2024 Update Available for Public Comment |
Bergeson & Campbell, P.C. |
